Fraxiparin antithrombotics

Description Results

symptomatic thromboembolism event 0.29 [0.11; 0.80]

total bleeding 2.09 [1.80; 2.44]

major Bleeding 2.51 [1.91; 3.30]

wound hematoma 1.88 [1.55; 2.29]

transfusin 1.65 [1.34; 2.03]

all cause death 0.45 [0.19; 1.02]

Pulmonary embolism 0.25 [0.05; 1.18]

all cause death 0.51 [0.05; 5.55]

Bleeding 0.34 [0.04; 3.23]

Pulmonary embolism 0.25 [0.03; 2.25]

Deep vein thrombosis 0.80 [0.47; 1.35]

minor bleeding 5.00 [0.60; 41.55]

VTE (symptomatic or asymptomatic) 0.20 [0.02; 1.66]

symptomatic VTE 1.00 [0.06; 15.63]

Nadroparin 2850 anti-Xa units (n=2247)

vs.

Placebo (n=2251)

Blind

Sample size: 2247/2251

Primary endpoint:

FU duration:

Fraxiparin (n=203)

vs.

Unfractionated heparin (n=206)

Sample size: 203/206

Primary endpoint:

FU duration:

0.3 ml sc fraxiparine 2 hours before the operation and self administered daily (except the firstvtwo doses) for 4 days after surgeryn/x (n=61)

vs.

no treatment (n=61)

Parallel groups

Sample size: 61/61

Primary endpoint:

FU duration: 4 days